This inventor holds 2 USPTO granted patents. Top assignee: Ranbaxy Laboratories, Inc.. Active years: 2001-2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2005
Title: Naresh Talwar: Innovator in Pharmaceutical Drug Delivery Systems
Introduction
Naresh Talwar is a prominent inventor based in New Delhi, India. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative drug delivery systems. With a total of 2 patents, his work focuses on enhancing the efficacy of drug administration for better therapeutic outcomes.
Latest Patents
Naresh Talwar's latest patents include an orally administered drug delivery system that provides both temporal and spatial control. This pharmaceutical composition, available in the form of tablets or capsules, combines various components such as a drug, a gas generating component, a swelling agent, and a viscolyzing agent. The formulation is designed to ensure that the drug is effectively delivered to the patient, optimizing therapeutic results. A preferred formulation includes 69.9% ciprofloxacin base, along with other excipients, ensuring sustained release and effective treatment.
Career Highlights
Naresh Talwar has been associated with Ranbaxy Laboratories, Inc., where he has contributed to the advancement of pharmaceutical technologies. His innovative approaches have positioned him as a key figure in the industry, focusing on improving drug delivery mechanisms.
Collaborations
Throughout his career, Naresh has collaborated with notable professionals in the field, including Himadri Sen and John Nicholas Staniforth. These collaborations have further enriched his research and development efforts.
Conclusion
Naresh Talwar's contributions to pharmaceutical drug delivery systems exemplify his commitment to innovation in healthcare. His patents reflect a deep understanding of drug formulation and delivery, paving the way for more effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
